Assignee profile:

Kringle Pharma Inc.

City:

Osaka

Country:

Japan

Published Applications:

19

Last publication date:

2025-12-18

Patent Grants:

13

Last grant date:

2020-07-07

Top Inventors for applications by Kringle Pharma Inc.

These are the the leading inventors for applications assigned to Kringle Pharma Inc.:

Recent patent applications by Kringle Pharma Inc.

Kringle Pharma Inc. based in Osaka, JP has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2025-12-18
US20250381247A1
Human necessities

SPINAL CORD INJURY THERAPEUTIC TARGETING FROM ACUTE PHASE TO SUBACUTE PHASE

#2 | 2025-06-05
US20250177486A1
Human necessities

THERAPEUTIC AGENT FOR SPINAL CORD INJURY

#3 | 2019-04-25 ✅ Patent 10,702,582 granted on 2020-07-07
US20190117732A1
Human necessities

HGF preparation suitable for treatment of neurological disorders

#4 | 2017-11-23 ✅ Patent 10,213,485 granted on 2019-02-26
US20170333527A1
Human necessities

HGF preparation suitable for treatment of neurological disorders

#5 | 2014-02-27
US20140056910A1
Human necessities

THERAPEUTIC AGENT FOR CANCER HAVING REDUCED SENSITIVITY TO MOLECULAR TARGET DRUG AND PHARMACEUTICAL COMPOSITION FOR ENHANCING SENSITIVITY TO MOLECULAR TARGET DRUG

#6 | 2012-06-14 ✅ Patent 8,383,588 granted on 2013-02-26
US20120149642A1
Chemistry; metallurgy

Fibrosis inhibitor for implanted organ

#7 | 2012-03-15
US20120064090A1
Human necessities

THERAPEUTIC AGENT FOR CANCER HAVING REDUCED SENSITIVITY TO MOLECULAR TARGET DRUG AND PHARMACEUTICAL COMPOSITION FOR ENHANCING SENSITIVITY TO MOLECULAR TARGET DRUG

#8 | 2012-01-26 ✅ Patent 8,518,880 granted on 2013-08-27
US20120021040A9
Human necessities

Therapeutic agent for spinal cord injuries

#9 | 2011-11-03 ✅ Patent 8,278,270 granted on 2012-10-02
US20110269944A1
Chemistry; metallurgy

HGF precursor protein variant and active protein thereof

#10 | 2010-12-23
US20100322998A1
Human necessities

SKIN ULCER PREVENTIVE CURATIVE AGENT CONTAINING HUMAN RECOMBINANT HGF

#11 | 2010-07-01 ✅ Patent 8,575,099 granted on 2013-11-05
US20100168003A1
Human necessities

Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereof

#12 | 2010-06-03 ✅ Patent 8,076,289 granted on 2011-12-13
US20100137217A1
Chemistry; metallurgy

Fibrosis inhibitor for implanted organ

#13 | 2010-04-01
US20100081617A1
Human necessities

THERAPEUTIC AGENT FOR SPINAL CORD INJURIES

#14 | 2009-09-17 ✅ Patent 8,461,112 granted on 2013-06-11
US20090233863A1
Human necessities

HGF preparation

#15 | 2009-08-20 ✅ Patent 8,003,607 granted on 2011-08-23
US20090209463A1
Chemistry; metallurgy

HGF precursor protein variant and active protein thereof

#16 | 2008-11-06 ✅ Patent 7,696,170 granted on 2010-04-13
US20080274960A1
Chemistry; metallurgy

Fibrosis inhibitor for implanted organ

#17 | 2007-09-13 ✅ Patent 7,563,768 granted on 2009-07-21
US20070213261A1
Human necessities

Asthma preparation

#18 | 2007-08-23 ✅ Patent 7,838,494 granted on 2010-11-23
US20070197433A1
Human necessities

Differentiation- or regeneration-inducing agent for alveoli

#19 | 2005-07-28 ✅ Patent 7,807,177 granted on 2010-10-05
US20050164918A1
Chemistry; metallurgy

Segment of glycosylation-deficient HGFalpha-chain

Also check out KRINGLE PHARMA INC.'s (Osaka, Japan) applicant profile with 4 patent applications submitted.

AssigneeID:

56431 ⎘